News & Updates
Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying esophageal cancer patients for treatment with KEYTRUDA using Combined Positive Score (CPS) ≥ 10.1 In Europe, KEYTRUDA…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced data on a new gene editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). The Company reported these data in an oral presentation at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers meeting, being…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema (HAE). “Over the past…
Read More
Mycrodose Therapeutics Receives US DEA Schedule I License to Research Four (4) Psychedelic Compounds
Excerpt from the Press Release: Mycrodose Therapeutics is pleased to announce that the company has been approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds at their San Diego, California laboratory. The company’s Schedule…
Read More
Excerpt from the Press Release: If you thought you were familiar with the SARS-CoV-2 spike protein, think again. According to a new study, the spike protein has a secret feature—a starting gate. It consists of glycans. When the gate is closed, the spike protein’s receptor binding domain (RBD) stays hidden, safe from the prying eyes…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a global Phase 2 clinical study of balstilimab monotherapy in…
Read More
Excerpt from the Press Release: BALTIMORE and PALO ALTO, Calif., Aug. 20, 2021 /PRNewswire/ — A novel machine learning based blood testing technology that could help to increase detection of early-stage lung cancer demonstrated promising results in a study published in Nature Communications1. Delfi Diagnostics Inc.’s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA…
Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf…
Read More
Excerpt from the Press Release: Immunization with a protein-based immunogen, DYAI-100, a receptor binding domain (RBD) of SARS-CoV-2, resulted in potent B cell immunity in preclinical studies, with strong serological recognition of the original SARS-CoV-2 virus and major variants of concern (Alpha, Beta, Gamma, and Delta; “VOCs”). The sera of vaccinated mice demonstrated potent neutralization…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?